The efficacy and safety of the preprandial injection of insulin lispro was compared with the oral administration of @entity5217 in @entity1 with early type 2 @entity6 . In this open-label, multicenter study, 143 @entity1 with a glucagon-stimulated increase in C-peptide of at least 0.4 nmol/L were randomized to receive preprandial insulin lispro (LP) or @entity5217 (GB) for 26 weeks. Seventy-five @entity1 received LP (51 male/24 female; age 40 to 70 years, duration of @entity6 4.4 +/- 2.9 years) and 68 @entity1 received GB (39 male/29 female; age 39 to 70 years; duration of @entity6 4.3 +/- 3.4 years). After 12 weeks, mean 90 minute blood @entity413 excursions were 0.9 +/- 1.0 mmol/L for LP and 1.8 +/- 1.2 mmol/L for GB (p < 0.0001). After 24 weeks, mean blood @entity413 excursions were 1.0 +/- 1.1 mmol/L for LP and 1.7 +/- 1.2 mmol/L for GB (p = 0.002). Body weight decreased slightly from 87.2 +/- 2.3 to 86.5 +/- 12.2 kg in the LP group and increased from 84.1 +/- 13.7 to 84.4 +/- 13.3 kg in the GB group. LP versus GB induced changes from baseline to endpoint in fasting C-peptide (nmol/L), @entity2690 and insulin levels (pmol/L) were - 0.2 +/- 0.4 versus - 0.1 +/- 0.6 (p = 0.04), - 11.2 +/- 26.0 versus - 1.1 +/- 17.3 (p = 0.03), and - 27.8 +/- 147.4 versus + 32.6 +/- 286.2 (not significant), respectively. @entity4051 c at baseline was 7.5 +/- 1.0 % for LP and 7.7 +/- 1.2 % for GB and did not change significantly in either group during the investigation. No significant difference was observed between the groups with respect to hypoglycemic episodes. Treatment with LP improved postprandial blood @entity413 control more than GB without increasing body weight or hypoglycemic episodes. In addition, use of LP was associated with a decrease in fasting C-peptide and @entity2690 levels, suggesting a potential down regulation of endogenous insulin production and improved @entity2690 processing efficiency.

Metabolic effects of mealtime insulin lispro in comparison to XXXX in early type 2 @entity6 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity4051 :: ('3039', 'Gene') :: ['HbA 1'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity5217 :: ('MESH:D005905', 'Chemical') :: ['glibenclamide'] @entity2690 :: ('3630', 'Gene') :: ['proinsulin'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity5217 :: (MESH:D005905,Chemical) :: ['glibenclamide']
